ILMN Illumina Inc

$373.10
$4.55 (1.23%)

ILMN Stock Analysis Overview

What this means: Illumina Inc (ILMN) gets an Overall Rank of 51, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. ILMN's 51 means that it ranks higher than 51% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full ILMN report

Illumina Inc (ILMN) Analyst Forecast

Next 12 months ➝Current Price$373.1052-week High$380.7652-week Low$196.78MEAN$330.27-11.48%HIGH$370.00-0.83%LOW$220.00-41.03%
  • Last Price$373.10
  • Previous Close$368.55
  • Change $4.55
  • Open$372.63
  • Volume698,858
  • Avg. Volume (100-day)1,271,667
  • Market Capitalization$55B
  • Days Range $371.22 - $377.42
  • 52-week Range $196.78 - $380.76
  • Dividend Yield
  • Ex. Dividend Date
  • P-E58.8
  • EPS6.35
  • Earnings Date08/03/2020
  • SectorHealthcare
  • IndustryDiagnostics & Research
  • Avg. Analyst Rec.
  • Beta0.806
  • PEG Ratio5.49
  • Volatility0.35
  • Average True Range0.03
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (73% of 2019 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 17% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.